{"organizations": [], "uuid": "745a3132040ae775e3f0e276ab16b5258cedcb51", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pear-therapeutics-sandoz-announce/brief-pear-therapeutics-sandoz-announce-deal-to-commercialize-prescription-digital-therapeutics-idUSFWN1RV0XN", "country": "US", "domain_rank": 408, "title": "BRIEF-Pear Therapeutics, Sandoz Announce Deal To Commercialize Prescription Digital Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.101, "site_type": "news", "published": "2018-04-19T04:07:00.000+03:00", "replies_count": 0, "uuid": "745a3132040ae775e3f0e276ab16b5258cedcb51"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pear-therapeutics-sandoz-announce/brief-pear-therapeutics-sandoz-announce-deal-to-commercialize-prescription-digital-therapeutics-idUSFWN1RV0XN", "ord_in_thread": 0, "title": "BRIEF-Pear Therapeutics, Sandoz Announce Deal To Commercialize Prescription Digital Therapeutics", "locations": [], "entities": {"persons": [], "locations": [{"name": "sandoz", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sandoz", "sentiment": "negative"}, {"name": "novartis", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - Pear Therapeutics:\n* PEAR THERAPEUTICS AND SANDOZ ANNOUNCE DEAL TO COMMERCIALIZE PRESCRIPTION DIGITAL THERAPEUTICS\n* PEAR THERAPEUTICS - DEAL WITH SANDOZ, A DIVISION OF NOVARTIS, TO COMMERCIALIZE ITS TWO LEAD PRODUCTS, RESET AND RESET-O\n* PEAR THERAPEUTICS SAYS DEAL INCLUDES RESEARCH AND DEVELOPMENT FUNDING, COMMERCIAL MILESTONES, AND A PROFIT SPLIT ON NET SALES OF BOTH THERAPEUTICS\n* PEAR THERAPEUTICS SAYS SANDOZ WILL ASSUME RESPONSIBILITY FOR GLOBAL COMMERCIAL LAUNCH OF RESET, AND RESET-O\n* PEAR THERAPEUTICS- PEAR WILL CONTINUE TO DEVELOP BOTH DIGITAL THERAPEUTICS AND WILL ALSO SUPPORT PATIENT SERVICES THROUGH ITS DIGITAL HUB SERVICE Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T04:07:00.000+03:00", "crawled": "2018-04-19T14:39:22.000+03:00", "highlightTitle": ""}